» Articles » PMID: 25497442

Brain Structure in People at Ultra-high Risk of Psychosis, Patients with First-episode Schizophrenia, and Healthy Controls: a VBM Study

Overview
Journal Schizophr Res
Specialty Psychiatry
Date 2014 Dec 16
PMID 25497442
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Early intervention research in schizophrenia has suggested that brain structural alterations might be present in subjects at high risk of developing psychosis. The heterogeneity of regional effects of these changes, which is established in schizophrenia, however, has not been explored in prodromal or high-risk populations. We used high-resolution MRI and voxel-based morphometry (VBM8) to analyze grey matter differences in 43 ultra high-risk subjects for psychosis (meeting ARMS criteria, identified through CAARMS interviews), 24 antipsychotic-naïve first-episode schizophrenia patients and 49 healthy controls (groups matched for age and gender). Compared to healthy controls, resp., first-episode schizophrenia patients had reduced regional grey matter in left prefrontal, insula, right parietal and left temporal cortices, while the high-risk group showed reductions in right middle temporal and left anterior frontal cortices. When dividing the ultra-high-risk group in those with a genetic risk vs. those with attenuated psychotic symptoms, the former showed left anterior frontal, right caudate, as well as a smaller right hippocampus, and amygdala reduction, while the latter subgroup showed right middle temporal cortical reductions (each compared to healthy controls). Our findings in a clinical psychosis high-risk cohort demonstrate variability of brain structural changes according to subgroup and background of elevated risk, suggesting frontal and possibly also hippocampal/amygdala changes in individuals with genetic susceptibility. Heterogeneity of structural brain changes (as seen in schizophrenia) appears evident even at high-risk stage, prior to potential onset of psychosis.

Citing Articles

The potential role of the p75 receptor in schizophrenia: neuroimmunomodulation and making life or death decisions.

Chandra J Brain Behav Immun Health. 2024; 38:100796.

PMID: 38813083 PMC: 11134531. DOI: 10.1016/j.bbih.2024.100796.


Using brain structural neuroimaging measures to predict psychosis onset for individuals at clinical high-risk.

Zhu Y, Maikusa N, Radua J, Samann P, Fusar-Poli P, Agartz I Mol Psychiatry. 2024; 29(5):1465-1477.

PMID: 38332374 PMC: 11189817. DOI: 10.1038/s41380-024-02426-7.


The Relationship Between Grey Matter Volume and Clinical and Functional Outcomes in People at Clinical High Risk for Psychosis.

Tognin S, Richter A, Kempton M, Modinos G, Antoniades M, Azis M Schizophr Bull Open. 2022; 3(1):sgac040.

PMID: 35903803 PMC: 9309497. DOI: 10.1093/schizbullopen/sgac040.


Clinical, Brain, and Multilevel Clustering in Early Psychosis and Affective Stages.

Dwyer D, Buciuman M, Ruef A, Kambeitz J, Dong M, Stinson C JAMA Psychiatry. 2022; 79(7):677-689.

PMID: 35583903 PMC: 9118078. DOI: 10.1001/jamapsychiatry.2022.1163.


Aberrant cortical surface and cognition function in drug-naive first-episode schizophrenia.

Wei Q, Yan W, Zhang R, Yang X, Xie S Ann Gen Psychiatry. 2022; 21(1):4.

PMID: 35144626 PMC: 8830089. DOI: 10.1186/s12991-022-00381-7.